ZFGN - Why Q3 Is Critical For Rhythm Pharmaceuticals
Rhythm Pharmaceuticals (RYTM) is approaching a critical period. In Q3'19 the company is expected to report data from two phase 3 trials of its drug setmelanotide which are the major focus of this article.
Setmelanotide in POMC deficiency obesity
Setmelanotide is an agonist of the melanocortin type 4 receptor (MC4R), activation of which is associated with satiety (a state of fullness) and increased energy expenditure. In select genetic disorders where activation of the MC4R is deficient, high appetite and increases in body weight occur. As such, setmelanotide may be of use in these